HC Wainwright Lowers Valneva (NASDAQ:VALN) Price Target to $20.00

Valneva (NASDAQ:VALN) had its target price cut by equities research analysts at HC Wainwright from $23.00 to $20.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 251.49% from the stock’s current price.

Valneva Stock Down 1.9 %

Valneva stock opened at $5.69 on Friday. The firm has a 50 day simple moving average of $6.80 and a 200 day simple moving average of $7.46. The company has a current ratio of 2.63, a quick ratio of 2.15 and a debt-to-equity ratio of 0.97. Valneva has a 1-year low of $5.58 and a 1-year high of $14.49. The firm has a market capitalization of $396.24 million, a price-to-earnings ratio of -13.88 and a beta of 2.17.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. The firm had revenue of $40.97 million during the quarter, compared to analyst estimates of $46.83 million. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. On average, analysts predict that Valneva will post 0.02 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. lifted its holdings in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 as of its most recent filing with the SEC. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.